Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
IntriCon Corporation is a medical instruments & supplies business based in the US. IntriCon Corporation shares (IIN) are listed on the NASDAQ and all prices are listed in US Dollars. IntriCon Corporation employs 762 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$17.58|
|52-week range||$11.63 - $28.16|
|50-day moving average||$19.76|
|200-day moving average||$22.02|
|Wall St. target price||$28.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.14|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||4.21%|
|1 month (2021-09-24)||-12.32%|
|3 months (2021-07-23)||-25.06%|
|6 months (2021-04-23)||-30.27%|
|1 year (2020-10-23)||34.92%|
|2 years (2019-10-23)||-7.62%|
|3 years (2018-10-23)||43.5|
|5 years (2016-10-21)||181.28%|
Valuing IntriCon Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IntriCon Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IntriCon Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 120x. In other words, IntriCon Corporation shares trade at around 120x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IntriCon Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.6 million.
The EBITDA is a measure of a IntriCon Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$119.7 million|
|Operating margin TTM||3.57%|
|Gross profit TTM||$26.2 million|
|Return on assets TTM||2.22%|
|Return on equity TTM||1.45%|
|Market capitalisation||$153.5 million|
TTM: trailing 12 months
There are currently 174,518 IntriCon Corporation shares held short by investors – that's known as IntriCon Corporation's "short interest". This figure is 6.9% down from 187,479 last month.
There are a few different ways that this level of interest in shorting IntriCon Corporation shares can be evaluated.
IntriCon Corporation's "short interest ratio" (SIR) is the quantity of IntriCon Corporation shares currently shorted divided by the average quantity of IntriCon Corporation shares traded daily (recently around 28376.910569106). IntriCon Corporation's SIR currently stands at 6.15. In other words for every 100,000 IntriCon Corporation shares traded daily on the market, roughly 6150 shares are currently held short.
However IntriCon Corporation's short interest can also be evaluated against the total number of IntriCon Corporation shares, or, against the total number of tradable IntriCon Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IntriCon Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 IntriCon Corporation shares in existence, roughly 20 shares are currently held short) or 0.0207% of the tradable shares (for every 100,000 tradable IntriCon Corporation shares, roughly 21 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against IntriCon Corporation.
Find out more about how you can short IntriCon Corporation stock.
We're not expecting IntriCon Corporation to pay a dividend over the next 12 months.
IntriCon Corporation's shares were split on a 3:2 basis on 29 June 1997. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your IntriCon Corporation shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for IntriCon Corporation shares which in turn could have impacted IntriCon Corporation's share price.
Over the last 12 months, IntriCon Corporation's shares have ranged in value from as little as $11.63 up to $28.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IntriCon Corporation's is 1.3772. This would suggest that IntriCon Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology, and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers. In addition, it offers professional audio headset products used for emergency response needs in the fire, law enforcement, safety, aviation, and military markets; and a line of miniature ear-and head-worn devices used by performers and support staff in the music and stage performance markets. The company sells its hearing device products, and medical and professional audio communications products directly to hearing instrument manufacturers, distributors, and partnerships; and microphone products to the radio communication and professional audio industries, as well as markets and sells hearing aid devices directly to consumers through direct mail advertising, Internet, and call center. The company was formerly known as Selas Corporation of America and changed its name to IntriCon Corporation. The company was incorporated in 1930 and is headquartered in Arden Hills, Minnesota.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.